Three-Year Post-Transplant Outcome of Desensitized Mechanical Circulatory Support Patients Awaiting Heart Transplantation
1Seoul St. Mary's Hospital, Seoul, Korea, Republic of, 2Cedars-Sinai Heart Institute, Los Angeles, CA
Meeting: 2020 American Transplant Congress
Abstract number: 182
Keywords: Heart, Mechnical assistance, Sensitization
Session Name: Heart Transplantation: It's All About the Outcomes
Session Type: Oral Abstract Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:45pm
Presentation Time: 3:51pm-4:03pm
*Purpose: Up to 30% of durable mechanical circulatory support (MCS) patients (pts) develop panel reactive antibody (PRA) screen >= 10%. In our program, desensitization (DS) is considered for pts with PRAs>50%. It has also been reported that sensitized MCS pts may have less humoral response post-transplant (HTx) following removal of the MCS device. We sought to investigate this observation in our sensitized MCS pts undergoing DS followed by HTx.
*Methods: Between 2010-16, 21 MCS pts who underwent DS were compared to a control group who underwent DS not on MCS support. PRAs were assessed at baseline and 2-4 weeks after DS. Post-HTx outcome included 3-year survival, freedom from cardiac allograft vasculopathy (CAV), freedom from non-fatal major adverse cardiac events (NF-MACE), and freedom from rejection including any treated rejection (ATR), acute cellular rejection (ACR), and antibody-mediated rejection (AMR). Infection complications requiring IV antibiotics, history of septic shock and death due to infection within 3 years after HTx were also evaluated.
*Results: DS regimens in both groups were similar and included combinations of rituximab/IVIG and plasmapheresis/bortezomib. Desensitized MCS pts showed significantly higher baseline peak PRA (91.8% vs. 83.6%, p=0.046) and higher PRA reduction after DS (21.8% vs. 5.4%, p=0.022) compared with control group. Pts on MCS support appear to have numerically lower incidence of AMR with comparable three-year survival, freedom from CAV, NF-MACE, ATR and ACR. Infection complications within 3 years were not different between groups.
*Conclusions: DS for MCS pts showed significant PRA reduction, resulting in an expansion of their donor pool. Post-HTx outcome of desensitized MCS pts showed non-inferiority to desensitized non-MCS pts revealing good efficacy and safety of DS. Removal of the MCS device at the time of transplant may be related with potentially less AMR post-HTx.
To cite this abstract in AMA style:Youn J, Cole R, Ramzy D, Kim E, Kobashigawa J, Moriguchi J. Three-Year Post-Transplant Outcome of Desensitized Mechanical Circulatory Support Patients Awaiting Heart Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/three-year-post-transplant-outcome-of-desensitized-mechanical-circulatory-support-patients-awaiting-heart-transplantation/. Accessed March 26, 2023.
« Back to 2020 American Transplant Congress